Tildrakizumab for Moderate-to-Severe Plaque Psoriasis: An Evidence-Based Review. (2021). Canadian Dermatology Today, 2(s03), 3–8. https://canadiandermatologytoday.com/article/view/2-s03-devani-prajapati